RVT 303

Drug Profile

RVT 303

Alternative Names: RVT-303

Latest Information Update: 13 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roivant Sciences
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glycogen storage disease type I; Glycogen storage disease type II

Most Recent Events

  • 09 Sep 2016 Phase-I clinical trials in Glycogen storage disease type I before September 2016 (Roivant Sciences pipeline, September 2016)
  • 09 Sep 2016 Phase-I clinical trials in Glycogen storage disease type II before September 2016 (Roivant Sciences pipeline, September 2016)
  • 09 Sep 2016 Roivant Sciences and Duke University agree to co-develop RVT 301 for glycogen storage disorders and orphan paediatric disorders (Roivant Sciences website, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top